

Paradigms

Pre-MENACTRIMS SYMPOSIUM

Thursday, December 4, 2026

Al Baraha 1, Intercontinental Hotel Festival City
Dubai, United Arab Emirates



REGISTER TODAY
Limited seats available

Unfolding the Subject Matter

Multiple sclerosis care increasingly requires information beyond clinical assessment alone. With growing recognition of subclinical disease activity, smouldering inflammation and progression independent of relapse activity, sensitive and clinically meaningful biomarkers are becoming increasingly important.

The ParadigMS pre-MENACTRIMS symposium will explore how technological, imaging and fluid biomarkers can provide complementary insights into disease activity, treatment response and progression. It will examine how digital tools capture real-world function, how advanced imaging reveals inflammatory and neurodegenerative processes, and how fluid biomarkers such as neurofilament light chain can detect biological changes not always apparent clinically.

A central theme will be how these different sources of information can be integrated with clinical judgement and patient characteristics to support more precise and personalised treatment decisions in MS care.

Target Audience

- Specialists
- Neurologists
- Practitioners
- Researchers in the field of MS

Registration

Registration is **complimentary and mandatory** and can be arranged via the online registration module available on the webpage.

Agenda

From Signals to Decisions: Technological, Imaging and Fluid Biomarkers in MS Treatment *Chair: Bassem Yamout, President of MENACTRIMS (AE)*

13:45-14:00	Registration
14:00-14:05	Welcome
14:05-14:20	Technological Biomarkers
14:20-14:35	Imaging Biomarkers
14:35-14:50	Fluid Biomarkers
14:50-15:00	Q&A and Panel Discussion

Bassem Yamout (AE) &
Celia Oreja-Guevara (ES)

Tjalf Ziemssen (DE)

Celia Oreja-Guevara (ES)

Melinda Magyari (DK)

All Faculty

Faculty



Prof. Bassem I. Yamout
Neurology Institute Director
Harley Street Medical Centre
Abu Dhabi, United Arab Emirates



Prof. Celia Oreja-Guevara
Vice Chair of Neurology
University Hospital San Carlos
Madrid, Spain



Prof. Tjalf Ziemssen
Director of the Center of Clinical
Neuroscience
Carl Gustav Carus University
Hospital
Dresden, Germany



Prof. Melinda Magyari
Consultant Neurologist
Danish Multiple Sclerosis Center
Copenhagen-Glostrup, Denmark

Learning Objectives

By the end of the symposium, participants should be able to:

- Understand how technological, imaging and fluid biomarkers can support more personalised treatment decisions in MS.
- Identify biomarker signals that may help detect subclinical disease activity, treatment response and risk of progression.
- Explore how digital and wearable technologies can complement clinic-based assessment by capturing real-world function over time.
- Recognise the imaging and fluid biomarkers with the greatest potential relevance for monitoring inflammation, neurodegeneration and smouldering disease.
- Consider the limitations, confounders and standardisation challenges that may affect biomarker interpretation and implementation in clinical practice.
- Integrate biomarker information with clinical judgement, MRI findings, patient characteristics and treatment goals, while considering applicability across different healthcare settings.

With thanks to our sponsor, who supports this Symposium without any involvement in the elaboration of the presentations.

sanofi

For more information visit:

2026.menactrims.org